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Abstract: Aromatase inhibitors (AI) induce painful musculoskeletal symptoms (AIMSS), 
which are dependent upon the pain transducing receptor TRPA1. However, since the AI 
concentrations required to engage TRPA1 in mice are higher than those found in the plasma of 
patients, we hypothesized that additional factors may cooperate to induce AIMSS. Here we 
report that the aromatase substrate androstenedione, unique among several steroid hormones, 
targeted TRPA1 in peptidergic primary sensory neurons in rodent and human cells expressing 
the native or recombinant channel. Androstenedione dramatically lowered the concentration of 
letrozole required to engage TRPA1. Notably, addition of a minimal dose of androstenedione 
to physiologically ineffective doses of letrozole and oxidative stress byproducts produces 
AIMSS-like behaviors and neurogenic inflammatory responses in mice. Elevated 
androstenedione levels cooperated with low letrozole concentrations and inflammatory 
mediators were sufficient to provoke AIMSS-like behaviors. The generation of such painful 
conditions by small quantities of simultaneously-administered TRPA1 agonists justifies 
previous failure to identify a precise link between aromatase inhibitors and AIMSS, 
underscoring the potential of channel antagonists to treat AIMSS. 
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Introduction 
Aromatase inhibitors (AIs) are a mainstay in the treatment of estrogen-sensitive breast 
cancer in postmenopausal women (1). AIs block the activity of aromatase cytochrome P450, 
which transforms the androgens, androstenedione and testosterone into the estrogens (estrone 
and 17β-estradiol, respectively) (2), which are responsible for cancer cell replication and growth 
(3). Unfortunately, one-third of patients treated with AIs develop muscular and joint pain 
(aromatase inhibitor-associated musculoskeletal symptoms, AIMSS), a condition that affects 
the quality of life of patients and limits adherence to AI therapy (4, 5, 6). The underlying 
mechanism of AIMSS is unknown and, accordingly, the treatment of AIMSS remains an unmet 
medical need.  
Recently, we reported that the transient receptor potential ankyrin 1 (TRPA1), a cation 
channel highly expressed by a subpopulation of primary sensory neurons of the dorsal root 
ganglia (DRG) (7), mediates AIMSS-like behaviors evoked by AIs in mice (8). TRPA1-
expressing nociceptors contain the neuropeptides substance P (SP) and calcitonin gene-related 
peptide (CGRP), which mediate neurogenic inflammation (9). Exogenous compounds, 
including allyl isothiocyanate (AITC), and endogenously generated reactive oxygen species 
(ROS) and their derivatives, have been identified as TRPA1 agonists (9-12). Similar to other 
reactive agonists (7), highly electrophilic conjugated Michael acceptor groups of exemestane 
(13) and nitrile moieties of letrozole and anastrozole (14) react with the thiol groups of specific 
cysteine and lysine residues to trigger TRPA1 and activate nociceptors (8). 
The ability to gate TRPA1 in vitro was confirmed in vivo by the observation that the pain-
like behaviors evoked by AIs in mice are abrogated by genetic deletion or pharmacological 
blockade of the channel (8). However, AI concentrations required for TRPA1 gating in vitro 
(8) are 1-2 order of magnitude higher than those found in patient plasma (15). In addition, an 
important proportion (30-40%), but not all, of treated patients develop the painful condition 
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(16, 17). These observations suggest that exposure to AIs is necessary, but not sufficient, to 
produce AIMSS, and that additional factors should cooperate with AIs to promote pain 
symptoms.  
Aromatase inhibition, while reducing downstream production of estrogens, moderately 
increases upstream plasma concentrations of androgens, including androstenedione (ASD) (18). 
Exemestane, a false aromatase substrate, blocks enzymatic activity by accommodating in the 
binding pocket that snugly encloses ASD (2). We reasoned that ASD, which retains some of 
the reactive chemical features of exemestane, such as the α,β-carbonyl moiety of the A ring and 
the ketone group at the 17 position, might target TRPA1 (Supplementary Fig. S1A). In this 
paper, we report that ASD, unique among several steroid hormones upstream to aromatase, 
targets the recombinant and native TRPA1, thereby, alone or in combination with oxidative 
stress byproducts, contributing to dramatically lowering the concentrations/doses of letrozole 
required to engage TRPA1 in vitro and produce TRPA1-dependent AIMSS-like behaviors in 
mice. 
 
Material and Methods 
Animals 
In vivo experiments and tissue collection were carried out according to the European 
Union (EU) guidelines and Italian legislation (DLgs 26/2014, EU Directive application 
2010/63/EU) for animal care procedures, and under University of Florence research permits 
#204/2012-B and #194/2015-PR. C57BL/6 mice (male, 20-25 g, 5 weeks; Envigo, Milan, Italy; 
N=284), littermate wild type (Trpa1+/+, N=22) and TRPA1-deficient (Trpa1-/-; N=22) mice 
(25-30 g, 5-8 weeks), generated by heterozygotes on a C57BL/6 background (B6.129P-
Trpa1tm1Kykw/J; Jackson Laboratories, Bar Harbor, ME, USA) (19), TRPV1-deficient mice 
(Trpv1-/-; B6.129X1-Trpv1tm1Jul/J; N=8) backcrossed with C57BL/6 mice (Trpv1+/+; N=8) for 
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at least 10 generations (Jackson Laboratories, Bar Harbor, ME, USA; 25-30 g, 5-8 weeks) or 
Sprague-Dawley rats (male, 75-100 g,  Envigo, Milan, Italy; N=24) were used. Animals were 
housed in a temperature- and humidity-controlled vivarium (12-hour dark/light cycle, free 
access to food and water). Behavioral experiments were done in a quiet, temperature-controlled 
(20 to 22 °C) room between 9 a.m. and 5 p.m., and were performed by an operator blinded to 
genotype and drug treatment. Animals were euthanized with inhaled CO2 plus 10-50% O2.  
 
Reagents 
The activating peptide of the human protease activated receptor 2 (hPAR2-AP) was 
synthesized by G. Cirino (University of Naples, Naples, Italy), and dissolved in distilled water. 
HC-030031 was synthesized as previously described (20). Letrozole, L-733,060, and CGRP8-
37 were from Tocris Bioscience (Bristol, UK). If not otherwise indicated, all other reagents 
were from Sigma-Aldrich (Milan, Italy). For in vitro experiments, all compounds were 
dissolved in 100% DMSO at 10 mM concentration. 
 
Cell culture and isolation of primary sensory neurons 
Naive untransfected HEK293 cells (American Type Culture Collection, Manassas, VA, 
USA; ATCC® CRL-1573™) were cultured according to the manufacturer’s instructions. 
HEK293 cells were transiently transfected with the cDNAs (1 µg) codifying for wild type (wt-
hTRPA1) or mutant 3C/K-Q (C619S, C639S, C663S, K708Q) (donated by D. Julius, 
University of California, San Francisco, CA, USA) (21) human TRPA1 (hTRPA13C/K-Q-
HEK293) using the jetPRIME transfection reagent (Euroclone, Milan, Italy) according to the 
manufacturer’s protocol. HEK293 cells stably transfected with cDNA for human TRPA1 
(hTRPA1-HEK293, donated by A.H. Morice, University of Hull, Hull, UK), or with cDNA for 
human TRPV1 (hTRPV1-HEK293, donated by M. J. Gunthorpe, GlaxoSmithKline, Harlow, 
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UK), or with cDNA for human TRPV4 (hTRPV4-HEK293, donated by N.W. Bunnett, Monash 
Institute of Pharmaceutical Sciences, Parkville, Australia), or with cDNA for both human 
TRPA1 and human TRPV1 (hTRPA1/V1-HEK293, hTRPA1/V1-HEK293, donated by A.H. 
Morice, University of Hull, Hull, UK) (22) were cultured as previously described (22). Human 
lung fibroblasts (IMR90; American Type Culture Collection, Manassas, VA, USA; ATCC® 
CCL-186™), which express the native TRPA1 channel, were cultured in DMEM 
supplemented with 10% FBS, 2 mM glutamine, 100 U penicillin and 100 µg/ml streptomycin. 
Cells were plated on glass coated (poly-L-lysine, 8.3 µM) coverslips and cultured for 2-3 days 
before being used for recordings. For all cell lines, the cells were used when received without 
further authentication. Primary DRG neurons were isolated from adult Sprague-Dawley rats 
and C57BL/6 or Trpa1+/+ and Trpa1-/- mice, and cultured as previously described (8). 
 
Cellular Recordings 
Intracellular calcium was measured as previously reported (8). Results are expressed as 
the percentage of increase of Ratio340/380 over the baseline normalized to the maximum effect 
induced by ionomycin (5 µM) (% Change in R340/380) or as the percentage of responding 
neurons, identified by KCl (50 mM). Whole-cell patch-clamp recordings were performed as 
reported elsewhere (8). Peak currents were normalized to cell membrane capacitance and 
expressed as mean of the current density (pA/pF) in averaged results. Currents were evoked in 
the voltage-clamp mode at a holding potential of -60 mV; signals were sampled at 1 kHz and 
low-pass filtered at 10 kHz. Capsaicin (0.1 or 1 µM) has been used to identify TRPV1-
expressing nociceptors. 
 
Behavioral experiments 
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For behavioral experiments, after habituation, mice (C57BL/6, Trpa1+/+ and Trpa1-/-, 
Trpv1+/+ and Trpv1-/-) were randomized into treatment groups, consistent with experimental 
design. First, we evaluated the acute nocifensive response and mechanical allodynia evoked by 
ASD, H2O2 (20 µl, intraplantar, i.pl.), letrozole (0.5 mg/kg, intragastric, i.g.), or their vehicles 
[5% DMSO, isotonic saline or 0.5% carboxymethylcellulose (CMC)], respectively. α-lipoic 
acid (100 mg/kg, i.g.), or its vehicle (0.5% CMC, i.g.), was administered 2 hours after letrozole 
(i.g.). Mechanical allodynia evoked by the combination of different doses of letrozole (i.g.), 
ASD (20 µl i.pl.), H2O2 (, 20 µl, i.pl.), or their vehicles was studied in C57BL/6, Trpa1+/+ and 
Trpa1-/- mice, with the timing of the various pharmacological interventions based on the timing 
of the responses to different stimuli. Mechanical allodynia and reduction in grip strength have 
been studied in C57BL/6 mice, Trpa1+/+ and Trpa1-/- mice treated with systemic D,L-
buthionine sulfoximine (BSO) (intraperitoneal, i.p.), ASD (i.p.) and letrozole (i.g.), or their 
vehicles (isotonic saline, 4% DMSO and 4% Tween 80 and 0.5% CMC, respectively), alone 
or in combination, with the timing of the various pharmacological interventions based on the 
timing of the responses to different stimuli.  
Acute nocifensive response. Immediately after i.pl. injection of the different compounds, 
C57BL/6, Trpa1+/+ and Trpa1-/- mice were placed in a Plexiglas chamber, and the total time 
spent licking and lifting the injected hind paw was recorded for 5 minutes, as previously 
described (23). 
Mechanical stimulation (von Frey hair test). Mechanical threshold was measured in 
C57BL/6, Trpa1+/+ and Trpa1-/-, Trpv1+/+ and Trpv1-/- mice before (basal level threshold) and 
after the various i.pl. or systemic treatments by using the up-and-down paradigm (24). The 
50% mechanical paw withdrawal threshold response (in g) was then calculated as previously 
described (24, 25). 
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Forelimb grip strength test. The grip strength test was performed with a grip strength 
meter (Ugo Basile, Varese, Italy), as previously reported (8, 26). The grip strength was 
measured in C57BL/6, Trpa1+/+ and Trpa1-/-, Trpv1+/+ and Trpv1-/- mice before and after the 
various treatments. 
 
H2O2 levels assay  
Sciatic nerves collected from euthanized C57BL/6 mice after various treatments were 
homogenized in 50 mM phosphate buffer (pH 7.4) containing 5 mM of sodium azide at 4°C 
for 60 seconds, centrifuged at 12,000xg for 20 minutes at 4°C, and the supernatant was used to 
determine the H2O2 content. H2O2 levels were detected by using the phenol red-HRPO method 
(27, 28) corrected by protein content and expressed as µmol/mg of proteins (29). 
 
Immunostaining  
C57BL/6 mice were anesthetized with a mixture (i.p.) of ketamine (90 mg/kg) and 
xylazine (3 mg/kg), and transcardially perfused with phosphate buffer saline followed by 4% 
paraformaldehyde. The sciatic nerve with the surrounding tissue was removed and embedded 
in paraffin. Immunofluorescence staining for 4-hydroxynonenal adducts and TRPA1 was 
performed as previously reported (30). 
 
Plasma protein extravasation 
BSO was given 30 minutes before letrozole, and ASD immediately after letrozole; mice 
were anesthetized 15 minutes after letrozole as previously described (10). HC-030031 (100 
mg/kg, i.p.) or its vehicle (4% DMSO plus 4% Tween80, i.p.), or a combination of L-733,060 
and CGRP8-37, (NK1/CGRP-RA; both 2 μmol/kg, i.v.) or its vehicle (isotonic saline), were 
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administered 60 minutes or 15 minutes before ASD, respectively. The extravasated dye was 
extracted from synovial tissue of the knee joint by overnight incubation in formamide, and 
assayed by spectrophotometry at 620 nm, as previously reported (20). 
 
Synovial fluid lavage 
The synovial fluid was collected from anesthetized mice treated with the combination of 
BSO (i.p.), letrozole (i.g.) and ASD (i.p.), or their vehicles (isotonic saline, 0.5% CMC and 4% 
DMSO plus 4% Tween80, respectively). BSO was given 30 minutes before letrozole and ASD 
immediately after letrozole. Synovial fluid was collected by instilling 3 times 0.1 ml of Hank’s 
Buffer plus 10 mM HEPES and 10 mM EDTA in the knee 15 minutes after letrozole. The 
neutrophil count was performed using standard morphological criteria on Diff-Quick stained 
cytospins. Data are expressed as total number of neutrophils in 100 µl of solution. 
 
CGRP-Like Immunoreactivity assay  
Slices (0.4 mm) of rat spinal cords were superfused with ASD or vehicle. Tissues were 
pre-exposed to capsaicin (10 µM, 20 minutes), superfused with a calcium-free buffer 
containing EDTA (1 mM), and pretreated with HC-030031 (50 µM) or capsazepine (10 µM). 
Superfusate fractions (4 ml) were collected at 10-minute intervals before, during, and after 
stimulus administration, freeze-dried, reconstituted with assay buffer, and analyzed for CGRP-
like immunoreactivity (LI) as previously described (8). CGRP-LI was calculated by subtracting 
the mean prestimulus value from those obtained during or after stimulation. Results are 
expressed as femtomoles of peptide per gram of tissue. Stimuli did not cross-react with CGRP 
antiserum.  
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ASD and letrozole level determination 
ASD levels were measured in mouse serum by using the Active® ASD 
Radioimmunoassay (Beckman Coulter, CA, USA), a competitive RIA with a sensitivity of 0.1 
nmol/L. Radiometric detection was performed using a 2470 WIZARD Automatic Gamma 
Counter (Perkin Elmer, IL, USA).  
Letrozole levels were measured by LC-MS/MS. Briefly, plasma samples (50 µl) were 
obtained from the blood collected at different time points (1 and 3 hours) after i.g. 
administration of letrozole (0.1 and 0.5 mg/kg). At 50 µl of plasma sample, 200 pg of d4-
letrozole was added. The sample was vortex-mixed for 10 seconds, then 50 µl of ZnSO4 (90 
mg/ml) diluted 1:4 with methanol was added, vortex-mixed for 30 seconds, and centrifuged at 
12,000 rpm for 10 minutes. Supernatant (50 µl) was injected in On-line column-switching SPE 
(CS-SPE). The CS-SPE consists of two high-performance-liquid chromatography (HPLC) 
systems connected by a six-port switching valve. In the first step, analytes of interest are 
retained on column 1 (trapping column, SPE Strata C18 20um, 20 x 2 mm, Phenomenex, 
Torrance, CA, USA), whereas the matrix components can be washed off. In the second step, 
column 1 is switched in back-flush to column 2 (analytical column, LUNA, 3 um, C18 20 x 2 
mm, Mercury MS Penomenex, Torrance, CA, USA). The mobile phases were the same for the 
trapping column and the analytical column, eluent A water with 0.1% formic acid and eluent 
B methanol. Samples were measured with a Perkin Elmer Sciex (Thornhill, Canada) API 365 
triple quadrupole mass spectrometer equipped with a Turbo IonSpray source, operating in 
positive ion mode, interfaced with a HPLC Perkin Elmer pump series 200. The capillary 
voltage was set to 5.5 kV. Heated turbo gas (450° C, air) at a flow rate of 10 l/minutes was 
used. The ion transitions recorded in Multiple Reaction Monitoring (MRM) were m/z 
286.2217.2 for letrozole and 290.2221.2 for d4-letrozole. A calibration curve was 
constructed for letrozole using the appropriate internal standard (d4-letrozole). Plasma samples 
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(50 µl) from control mice were spiked with different concentrations of letrozole (from 2 to 16 
ng/ml). A satisfying linearity was obtained for letrozole (r2=0.994). 
 
Data Analysis  
Data represent mean±SEM. Statistical analysis was performed by the unpaired two-tailed 
Student’s t-test for comparisons between two groups, and the ANOVA, followed by the 
Bonferroni post-hoc test, for comparisons between multiple groups (GraphPadPrism version 
5.00, San Diego, CA, USA). Agonist potency was expressed as half maximal effective 
concentration (EC50); that is, the molar concentration of an agonist producing 50% of the 
maximum measured effect. P<0.05 was considered statistically significant.  
 
Results  
ASD selectively activates the recombinant and native human TRPA1 by targeting key 
electrophilic amino acid residues 
In hTRPA1-HEK293 cells, but not in untransfected HEK293 cells, ASD evoked 
calcium responses in a concentration-dependent manner (EC50, 49 µM) (Fig. 1A and 
Supplementary Fig. S1B). Responses to both ASD and the TRPA1 agonist, AITC, were 
abrogated by HC-030031 (Fig. 1B). Consistently, hTRPA1-HEK293 cells superfused with 
ASD elicited concentration-dependent inward currents (Supplementary Fig. S1E), an effect 
blocked by HC-030031 (Fig. 1C) and absent in untransfected HEK293 cells (Fig. 1D). In 
hTRPV1-HEK293 and hTRPV4-HEK293, activated by the selective TRPV1 agonist, 
capsaicin, or the selective TRPV4 agonist, GSK1016790A, respectively, ASD failed to evoke 
calcium responses or inward currents (Fig. 1E and 1F). Notably, hTRPA13C/K-Q-HEK293 
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did not respond to AITC or ASD, while they did respond to the non-electrophilic TRPA1 
agonist, menthol (Fig. 1G and Supplementary Fig. S1D) (8). 
In IMR90 cells, which constitutively express the TRPA1 channel (31) and do not 
respond to capsaicin, indicating the absence of a functional TRPV1 channel (Fig. 1H), ASD 
produced concentration-dependent (EC50, 37 µM) calcium responses that were fully and 
selectively inhibited by HC-030031 (Fig. 1H and Supplementary Fig. S1C). Similar results 
were obtained in electrophysiology experiments, where ASD activated TRPA1-mediated 
inward currents that were entirely and selectively abolished by HC-030031 (Fig. 1I). TRPA1 
selectivity of HC-030031 in inhibiting ASD-evoked responses was supported by failure to 
affect responses produced by hPAR2-AP or KCl in hTRPA1-HEK293 or IMR90 (Fig. 1A-D, 
1H, 1I). Next, we wondered whether the other aromatase substrate, testosterone, or steroid 
hormones upstream to aromatase that maintain the α,β-carbonyl moiety of the A ring 
(progesterone, 17-hydroxy-progesterone), or the ketone group at the 17 position 
(dehydroepiandrostenedione), or other steroid hormones that retain the α,β-carbonyl moiety of 
the A ring (aldosterone, cortisol, corticosterone, deoxycorticosterone, 11-deoxycortisol), were 
able to activate hTRPA1-HEK293 cells. No hormone evoked a measurable response 
(Supplementary Fig. S1E). 
 
ASD excites DRG neurons by a prominent role of TRPA1 and, surprisingly, with the 
contribution of TRPV1 
ASD evoked concentration-dependent (EC50 = 27 µM) calcium responses in a subset of 
rat DRG neurons, identified by their ability to respond to KCl, AITC and capsaicin as 
nociceptors (23) (Fig. 2A and Supplementary Fig. S1F). Capsaicin-sensitive neurons that did 
not respond to AITC were also unresponsive to ASD (Fig. 2A). The percentages of ASD-
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responding and AITC-responding neurons out of the KCl-responding neurons were similar 
(Fig. 2B). Superimposable findings were obtained by electrophysiological recording (Fig. 3A). 
Surprisingly, the remarkable ASD selectivity for TRPA1 was challenged by experiments in rat 
DRG neurons. The selective TRPV1 antagonist, capsazepine, reduced both the calcium 
response and the inward currents evoked by ASD, and it abated the residual response observed 
in the presence of HC-030031 (Fig. 2C and 2D and Fig. 3A). The calcium response to ASD 
was, however, unaffected by the selective TRPV4 antagonist, HC-067047 (Fig. 2D). Results 
obtained in rat DRG neurons were replicated in mouse DRG neurons. Cells obtained from 
Trpa1-/- mice exhibited a residual calcium response to ASD that, being consistently unaffected 
by HC-030031, was abated by capsazepine (Fig. 2E). The percentages of ASD-responding and 
AITC-responding neurons out of the KCl-responding neurons were similar (Fig. 2F) in DRG 
neurons isolated from Trpa1+/+ mice. The percentage of neurons from Trpa1-/- mice that 
exhibited a residual calcium response to ASD did not exceed the percentage obtained in 
neurons from Trpa1+/+ mice (Fig. 2F). 
To confirm the contribution of TRPV1 in the overall response to ASD, we used 
hTRPA1/V1-HEK293 cells (22), where the calcium response evoked by ASD was reduced by 
both HC-030031 and capsazepine, and was abated solely by the combination of the two 
antagonists, while responses to AITC and capsaicin were fully attenuated by respective 
antagonists (Fig. 2G). Thus, TRPV1, when co-expressed with TRPA1, as constitutively 
happens in DRG neurons, appears to contribute to the response to ASD. 
CGRP release from slices of the rat dorsal spinal cord, an anatomical site enriched with 
terminals of TRPA1-positive peptidergic nociceptors, illustrates the ability of ASD to activate 
such neurons (8). The increased CGRP-LI outflow by ASD was abated by the removal of 
extracellular calcium, previous desensitization to capsaicin, or in the presence of HC-030031, 
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but only partially reduced by capsazepine (Fig. 2H). Thus, ASD elicits CGRP release from a 
subset of TRPV1-positive neurons via a neurosecretory process, mediated by TRPA1. 
 
ASD cooperates with letrozole and H2O2 to excite nociceptors in vitro 
To explore whether ASD cooperates with AIs and proinflammatory mediators to excite 
nociceptors via a TRPA1-dependent final common pathway, we used letrozole, the most 
prescribed AI in clinical practice (32). As a prototypical proinflammatory mediator, we 
selected the ROS H2O2, because oxidative stress is increased by breast cancer (33) and letrozole 
(34). In addition, the effect of letrozole (0.5 mg/kg, i.g.), at a dose that was previously shown 
to produce per se mechanical allodynia, was partially reduced by the antioxidant, α-lipoic acid 
(Supplementary Fig. S2). These observations suggest that the TRPA1-dependent letrozole-
evoked mechanical hypersensitivity (8) is partially due to ROS generation, which cooperates 
with the anticancer drug to target TRPA1.  
From the concentration-response curves of ASD, letrozole, and H2O2 (Fig. 3A-C), we 
selected subthreshold concentrations that were unable to elicit measurable inward currents in 
rat DRG neurons, and combined a per se inactive concentration of ASD with inactive 
concentrations of letrozole or H2O2 (ASD/letrozole or ASD/H2O2). Interestingly, we found that 
each combination evoked inward currents, which were abated by TRPA1 antagonism and 
reduced by TRPV1 antagonism (Fig. 3D). Finally, we identified an inactive combination of 
letrozole and H2O2 (Fig. 3E), and we found that adding an inactive ASD concentration to it 
triggered an inward current that was abated by HC-030031 and only partially reduced by 
capsazepine (Fig. 3E).  
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ASD cooperates with letrozole and H2O2 to produce local TRPA1-dependent 
mechanical allodynia  
Previous in vitro findings were translated to an in vivo setting. Injection of ASD (1-10 
nmol/paw) into the mouse paw did not evoke any acute nociceptive behavior (data not shown). 
However, 30 minutes after the injection, and for the following 2 hours, ASD produced a dose-
dependent mechanical allodynia (Fig. 4A and 4B) that was partially and completely abrogated 
by capsazepine and HC-030031, respectively (Fig. 4B). H2O2 injected in the mouse paw 
produced a dose-dependent mechanical allodynia that was entirely dependent on TRPA1 (Fig. 
4C). Similar to previous findings (8), systemic letrozole (0.1-0.5 mg/kg, i.g.) evoked a dose-
dependent, delayed (1-6 hours) mechanical allodynia that was abated by HC-030031 and 
unaffected by capsazepine (Fig. 4D). The combined administration of allodynia-evoking doses 
of ASD and letrozole produced an exaggerated pain-like response (Supplementary Fig. S3A).  
Next, we found doses of ASD and letrozole, or H2O2 and ASD, which, although per se 
ineffective, when given in combination, lowered the threshold for eliciting mechanical 
allodynia (Supplementary Fig. S3B and S3C). Finally, we identified ineffective combinations 
of ASD/letrozole, letrozole/H2O2, or H2O2/ASD that, when given simultaneously 
(letrozole/ASD/H2O2), caused mechanical allodynia (Fig. 4E). This response was partially 
reduced by capsazepine, completely reverted by HC-030031 (Fig. 4F), and absent in Trpa1-/- 
(Fig. 4G).   
 
ASD cooperates with letrozole and H2O2 to produce systemic TRPA1-dependent 
AIMSS-like behaviors and neurogenic inflammation 
In mice, letrozole (0.5 mg/kg, i.g.) has been reported to evoke TRPA1-dependent 
mechanical allodynia and a decrease in grip strength, two effects reminiscent of AIMSS (8). 
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The same dose of letrozole (0.5 mg/kg, i.g.) (8) increased H2O2 in the sciatic nerve tissue and 
slightly augmented ASD serum levels (Fig. 5A and 5C). BSO, by inhibiting γ-glutamylcysteine 
synthetase, causes systemic depletion of glutathione, and the ensuing increase in ROS (35). 
BSO (800 mg/kg, i.p.) increased mechanical allodynia and decreased forelimb grip strength 
through a TRPA1-dependent mechanism (Supplementary Fig. S4A), while, at the dose of 400 
mg/kg, it slightly increased H2O2 in the sciatic nerve tissue (Fig. 5C) without affecting pain-
like behaviors (Supplementary Fig. S4A). Finally, systemic administration of ASD (2 μg/kg, 
i.p.) caused, in mice, mechanical allodynia and reduced forelimb grip strength via TRPA1, with 
a partial contribution of TRPV1 (Supplementary Fig. S4B). ASD (2 μg/kg, i.p.) also increased 
H2O2 levels in the sciatic nerve (Fig. 5C).  
To better understand the contribution of ASD and oxidative stress to the AIMSS-like 
behaviors, a low dose of ASD (0.2 μg/kg, i.p.) that failed to affect H2O2 generation (Fig. 5C), 
as well as mechanical allodynia and forelimb grip strength, (Supplementary Fig. S4B) was 
used. This same dose slightly increased hormone plasma concentration to levels comparable to 
those produced by a dose of letrozole (0.5 mg/kg, i.g.) that caused pain-like behaviors (Fig. 5A 
and Fig. 4D). In mice, 1 hour after oral administration of letrozole (0.1 and 0.5 mg/kg), drug 
concentrations in plasma were 13.5 ± 2.0 ng/ml (n = 4) and 55.3 ± 4.8 ng/ml (n = 4), 
respectively, whereas 3 hours after dosing, plasma concentrations were 8.41 ± 1.0 ng/ml (n = 
4) and 45.4 ± 6.11 ng/ml (n = 4), respectively. Notably, the plasma concentration of 0.5 mg/kg 
letrozole measured at 1 hour after dosing was similar to that found previously (8). Systemic 
BSO (400 mg/kg, i.p.), letrozole (0.1 mg/kg, i.g.) and ASD (0.2 g/kg, i.p.), which per se, or 
in combinations (letrozole/ASD, BSO/ASD or BSO/letrozole), did not affect behavioral 
responses, when given simultaneously caused remarkable mechanical allodynia and decreased 
forelimb grip strength (Fig. 5D and 5E). The triple combination of BSO, letrozole, and ASD 
increased H2O2 levels in the sciatic nerve (Fig. 5C). However, the increase equals that evoked 
 18 
by BSO (400 mg/kg) alone. Finally, the remarkable increase in 4-hydroxynonenal staining in 
the sciatic nerve allowed us to localize the oxidative stress generation within the neural 
structure (Fig. 5H). Behavioral responses evoked by the triple combination were partially and 
totally reverted by capsazepine and HC-030031, respectively (Fig. 5D and 5E), and were absent 
in Trpa1-/- mice, but unaffected in Trpv1-/- mice (Fig. 5F and 5G).  
Finally, the combination of BSO (400 mg/kg, i.p.), letrozole (0.1 mg/kg, i.g.) and ASD 
(0.2 g/kg, i.p.), which produced AIMSS-like behaviors, increased Evans blue dye 
extravasation in the synovial tissue and the number of neutrophils in the synovial fluid of mouse 
knee joint (Fig. 5I and 5J). Both responses were reduced by pretreatment with HC-030031 or 
a combination of L733,060 and CGRP8-37 (both 2 µmol/kg, i.v.) (Fig. 5I and 5J). These findings 
indicate that the letrozole/ASD/BSO combination via TRPA1 promotes two typical neurogenic 
inflammatory responses, such as plasma protein and neutrophil extravasation (9). 
 
Discussion 
We found that ASD, unique among several steroid hormones, activates TRPA1, thereby 
promoting AIMSS-like responses. ASD behaves as a TRPA1 agonist across species, as it 
engages both the recombinant and native human channel and the rat and mouse channel. TRPA1 
activation by ASD, similar to other electrophilic agonists (7), requires the presence of three 
cysteine (C619, C639, C663) and one lysine (K708) key residues. Furthermore, ASD exhibits 
a peculiar selectivity profile. Whereas in cells expressing only one channel (transfected 
HEK293 cells, IMR90 human fibroblasts) (31, 36), ASD is a selective TRPA1 agonist, 
surprisingly, in rodent DRG neurons, which express multiple TRP channels, TRPV1 
contributes to TRPA1-dependent ASD-evoked responses. Notably, DRG neurons from Trpa1-
/- mice maintained a residual responsiveness to ASD which was abolished by capsazepine. One 
possible explanation for this unexpected finding is that the TRPA1 protein remaining after the 
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homologous recombination, while lacking the domain required for channel activation by most 
agonists (37), including ASD itself, maintains the domain essential for TRPV1-dependent ASD 
activity. TRPV1 contribution to TRPA1-mediated responses evoked by ASD or other chemicals 
(22) was confirmed in cells expressing the recombinant forms of both the TRPA1 and TRPV1 
(hTRPA1/V1-HEK293) channels. Formation of heterotetramers (38, 39), or intracellular 
calcium movement initiated by TRPA1 gating that results in a secondary TRPV1 activation 
(40), may explain how ASD heterologously interregulates channel activities (41, 42). 
Notwithstanding, this peculiar selectivity pattern was not replicated in vivo as TRPA1 inhibition 
was sufficient to totally prevent ASD actions. 
Tenosynovitis and joint swelling are symptoms reported by patients treated with AIs (43). 
However, association with proinflammatory markers, including cytokines, such as interleukin-
6, has been excluded (44). The ability of ASD to release sensory neuropeptides or, in 
combination with letrozole and BSO, to provoke TRPA1-dependent SP/CGRP release, edema 
and neutrophil infiltration in the knee joint, suggests that neurogenic inflammation mediates the 
inflammatory component of AIMSS. The recent observation that, due to their electrophilic and 
reactive properties, exemestane, anastrozole and letrozole target TRPA1, thus evoking pain-
like responses and neurogenic inflammation, supported the hypothesis that channel activation 
in peptidergic nociceptors promotes AIMSS (8). However, while the three AIs target TRPA1 
with remarkable selectivity, they exhibit low potency at both human and rodent channels (8). 
Notably, the peak plasma concentration of letrozole measured in mice in the present study after 
the 0.5 mg/kg dose (~194 nM) is close to the maximum concentration reported in human plasma 
after a single therapeutic dose (2.5 mg) (~128 nM) (45). It must be underlined that the plasma 
concentrations found in mice and humans are 50-400 times lower than the threshold 
concentrations of letrozole able to gate in vitro the mouse, rat or human TRPA1 (>10 μM). This 
gap between plasma levels and threshold concentrations at TRPA1 argues against the 
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hypothesis that AIs per se cause AIMSS.  Elevated tissue concentrations due to high AI volumes 
of distribution (46) may still be insufficient for effective channel gating. Lack of evidence 
associating increased AI plasma levels with pain symptoms (45) further weakens the hypothesis 
that AIMSS results from an exclusive AI action. Similarly, attempts to associate serum ASD 
concentrations with AIMSS have failed (18). Thus, a direct cause-and-effect relationship 
between plasma levels of AIs or ASD and AIMSS has not been shown.  
TRPA1 is amenable to sensitization by a variety of endogenous proinflammatory and 
proalgesic mediators (47), and we previously reported that H2O2 or PAR2 stimulation 
exaggerated TRPA1-dependent responses evoked by AIs (8). The present novel finding that the 
aromatase substrate, ASD, activates TRPA1 proposes a novel paradigm to explain AIMSS 
generation. Multiple factors, concomitantly occurring in breast cancer patients treated with AIs, 
may cooperate to engage TRPA1, thus causing AIMSS-like behaviors. Letrozole (and probably 
other AIs) is the essential, although per se ineffective, initiating stimulus. Letrozole slightly 
augments ROS (34) and ASD concentrations (18). Breast cancer (33) or incidental 
inflammatory processes (48) may boost oxidative stress, thus increasing the possibility of the 
simultaneous presence of the three TRPA1 stimulants. However, the current hypothesis does 
not exclude that additional agents, able to activate or sensitize the TRPA1, may act along with 
AIs and ASD to reach the threshold for AIMSS generation. The present study, while showing 
that TRPV1 signaling negligibly contributes to ASD-evoked AIMSS-like behaviors, robustly 
underscores the paramount role of TRPA1. Thus, TRPA1 blockade by both new compounds 
currently under clinical scrutiny and old medicines recently identified as TRPA1 antagonists 
(49) may represent a new frontier to treat or prevent AIMSS.  
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Figure Legends 
 
Figure 1. ASD selectively activates the human TRPA1 channel. A, calcium response evoked 
by ASD (100 µM), AITC (5 µM) and hPAR2-AP (100 µM) in hTRPA1-HEK293 and in 
HEK293 cells. B, HC-030031 (HC03; 30 µM) abates the response to both ASD and AITC, but 
not to hPAR2-AP. C and D, ASD (50 µM) or AITC (100 µM), elicit inward currents in 
hTRPA1-HEK293, but not in HEK293 cells. HC03 (50 µM) does not affect responses to KCl 
(50 mM), but abolishes responses to either ASD or AITC. E and F, ASD (100 µM) is ineffective 
in hTRPV1-HEK293, activated by capsaicin (CPS; 0.1 µM), and in hTRPV4-HEK293, 
activated by GSK1016790A (GSK; 0.1 µM). G, hTRPA1 3C/K-Q HEK293 are insensitive to 
ASD (100 µM), but respond to menthol (100 µM), whereas wt-hTRPA1 respond to both 
compounds. H, IMR90 respond to ASD (100 µM) and AITC (1 µM), but not to CPS (5 µM). 
Responses to AITC and ASD, but not to hPAR2-AP (100 µM), are inhibited by HC03 (30 µM), 
but not by capsazepine (CPZ, 10 µM). I, In IMR90 fibroblasts ASD (100 µM) and AITC (100 
µM), but not hPAR2-AP (100 µM), evoke inward currents, which are abated by HC03 (50 
µM). Veh is the vehicle of ASD; (-) indicates the vehicle of antagonists. Each point/column is 
the mean±SEM of at least n=25 cells from 3-6 independent experiments for calcium recordings 
or of at least n=6 cells from 4-8 independent experiments for electrophysiological recordings. 
*P<0.05 vs. Veh, §P<0.05 vs. ASD or AITC. ANOVA and Bonferroni post hoc test.  
 
Figure 2. ASD activates the native TRPA1 channel expressed in rodent DRG neurons. A, 
typical tracings of calcium responses in rat DRG neurons that respond to ASD (100 µM), AITC 
(30 µM) and capsaicin (CPS; 0.1 µM) (black line), or solely to CPS (red line). B, percentage 
of DRG neurons (sensitive to 50 mM KCl) that respond to ASD, AITC or CPS. C and D, in rat 
DRG neurons concentrations of HC-030031 (HC03; 30 µM) and capsazepine (CPZ; 10 µM) 
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that selectively and completely attenuated AITC and CPS responses, respectively, partially 
inhibit the response to ASD that, however, is abated by their combination (HC03/CPZ). HC-
067047 (HC06; 10 µM) does not affect the response to ASD. E, ASD produces a calcium 
response in CPS-sensitive DRG neurons isolated from Trpa1+/+ mice. The residual response to 
ASD in neurons from Trpa1-/- mice is abated by CPZ. F, percentage of Trpa1+/+ or Trpa1-/- 
DRG neurons responsive to AITC, ASD and CPS. G, in hTRPA1/V1-HEK293 cells the 
calcium response to ASD is partially inhibited by HC03 or CPZ and abated by their 
combination (HC03/CPZ). Calcium responses to AITC (5 µM) and CPS (1 µM) are abolished 
by HC03 and CPZ, respectively. Each point/column represents the mean±SEM of at least n=25 
neurons from 3-7 independent experiments. *P<0.05 vs. Veh or Veh-Trpa1+/+, §P<0.05 vs. 
ASD, CPS, AITC or ASD-Trpa1+/+, #P<0.05 vs. ASD-Trpa1-/-. H, CGRP-LI outflow elicited 
by ASD (10-50 µM) from rat dorsal spinal cord slices is prevented by pre-exposure to CPS (10 
µM, 20 min; CPS-des) or by calcium removal (Ca2+-free) and is attenuated by HC03 (50 µM) 
and only partially reduced by CPZ (10 µM). Each column represents the mean±SEM of at least 
4 independent experiments running in duplicate. *P<0.05 vs. Veh, §P<0.05 vs. ASD 50 µM, 
#P<0.05 vs. HC03. Veh is the vehicle of ASD; (-) indicates the vehicle of antagonists. ANOVA 
and Bonferroni post hoc test.  
 
Figure 3. ASD potentiates TRPA1-mediated inward currents in the presence of subthreshold 
letrozole and/or proinflammatory stimuli in rat DRG neurons. A, ASD and AITC (100 µM) 
evoke inward currents (whole-cell patch-clamp recordings) in capsaicin (CPS; 1 µM)-sensitive 
rat DRG neurons. ASD-evoked currents are partially reduced by HC-030031 (HC03; 50 µM) 
or capsazepine (CPZ; 10 µM), which abated currents evoked by AITC or CPS, respectively. 
The combination of HC03 and CPZ abated the ASD-evoked currents. B and C, letrozole (LTZ) 
and H2O2 evoke concentration-dependent inward currents that are abolished by HC03 (50 µM). 
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D, inward currents elicited by a combination of ineffective concentrations of ASD (10 
µM)/LTZ (50 µM) or ASD (10 µM)/H2O2 (50 µM) are abolished by HC03 and reduced by 
CPZ. The combination with a lower concentration of ASD (1 µM) is ineffective. E, addition of 
a much lower concentration of ASD (30 nM) to the ineffective combination of LTZ (50 
µM)/H2O2 (50 µM) elicits inward currents, which are abated by HC03 and reduced by CPZ. 
Veh is the vehicle of ASD, LTZ or H2O2; (-) indicates the vehicle of antagonists. Results are 
mean±SEM of at least 4 independent experiments. *P<0.05 vs. Veh; §P<0.05 vs. LTZ, H2O2, 
ASD. ANOVA and Bonferroni post hoc test. 
 
Figure 4. ASD cooperates with letrozole and H2O2 to produce TRPA1-dependent local 
mechanical allodynia. A, diagram illustrating the treatment schedule before behavioral tests. 
B-D, In C57BL/6 mice, injection (20 μl) of ASD or H2O2 and administration of LTZ induce a 
dose and time-dependent mechanical allodynia that is reversed completely by HC03, and 
partially by CPZ. E and F, The combination of ineffective doses of LTZ, ASD and H2O2 evokes 
mechanical allodynia that is completely prevented by HC03, partially reduced by CPZ, and (G) 
absent in Trpa1-/- mice. BL, baseline threshold. VehASD, VehLTZ and VehH2O2 are the 
vehicle of ASD, LTZ and H2O2, respectively; (-) is the vehicle of antagonists. Results are mean 
± SEM of at least n=5 mice for each group. *P<0.05 vs. BL; §P<0.05 vs. (-); #P<0.05 vs. 
Trpa1+/+. ANOVA and Bonferroni post hoc test. 
 
Figure 5. Androstenedione cooperates with letrozole and H2O2 to evoke systemic TRPA1-
dependent AIMSS-like behaviors. A, ASD serum levels are similarly increased by systemic 
administration (↓) of ASD or letrozole (LTZ). B, diagram illustrating the treatment schedule 
before behavioral tests. C, LTZ or ASD increase H2O2 in homogenates of mouse sciatic nerve. 
Addition of ineffective doses of LTZ and ASD does not further increase H2O2 levels produced 
by BSO alone. D and E, ASD, LTZ and BSO alone or in dual combinations (ASD/LTZ; 
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ASD/BSO; LTZ/BSO) do not increase mechanical allodynia or decrease grip strength. 
However, their combination (BSO/LTZ/ASD) increases mechanical allodynia and decreases 
grip strength. Both responses are reverted by HC03 and attenuated by CPZ. F and G, changes 
in mechanical allodynia and grip strength induced by BSO/LTZ/ASD observed in 
Trpa1+/+mice are similar to those observed in Trpv1+/+ and abrogated in Trpa1-/- mice, but not 
in Trpv1-/- mice. H, BSO/LTZ/ASD (+++), but not their vehicles (---) increase 4-
hydroxynonenal (4-HNE) staining within the sciatic nerve. I and J, HC03 or the combination 
of L-733,060 and CGRP8-37 (NK1/CGRP-RA) attenuate increases in Evans blue dye 
extravasation in the knee joint synovial tissue, and in neutrophil number in synovial fluid 
evoked by BSO/LTZ/ASD. BL, baseline threshold. Scale bar, 100 µm. Veh is the vehicle of 
LTZ, ASD and BSO; VehASD, VehLTZ and VehBSO are the vehicle of ASD, LTZ and BSO, 
respectively; VehHC03/CPZ (D) and (-) (I, J) are the vehicle of antagonists. Results are 
mean±SEM of at least n=5 mice for each group. *P<0.05 vs. Veh (B), time 0 (C) or white 
columns or circle (D-J); §P<0.05 vs. Veh HC03/CPZ; #P<0.05 vs. Trpa1+/+; †P<0.05 vs. (-). 
ANOVA and Bonferroni post hoc test. 
 
